X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
varespladib (36) 36
index medicus (24) 24
atherosclerosis (17) 17
animals (15) 15
humans (15) 15
secretory phospholipase a (15) 15
darapladib (14) 14
inflammation (12) 12
cardiac & cardiovascular systems (10) 10
pharmacology & pharmacy (10) 10
varespladib methyl (10) 10
indoles - pharmacology (9) 9
low-density-lipoprotein (9) 9
mice (9) 9
acetates - pharmacology (8) 8
biochemistry & molecular biology (8) 8
group-v (8) 8
phospholipase (8) 8
acetates - therapeutic use (7) 7
atherosclerosis - drug therapy (7) 7
indoles - therapeutic use (7) 7
phospholipase a (7) 7
phospholipases a2, secretory - antagonists & inhibitors (7) 7
secretory phospholipase a2 (7) 7
benzaldehydes - therapeutic use (6) 6
male (6) 6
myocardial-infarction (6) 6
oximes - therapeutic use (6) 6
phospholipase a2 (6) 6
1-alkyl-2-acetylglycerophosphocholine esterase - antagonists & inhibitors (5) 5
artery-disease (5) 5
coronary-heart-disease (5) 5
disease models, animal (5) 5
expression (5) 5
lipoprotein-associated phospholipase a (5) 5
ly315920 (5) 5
peripheral vascular disease (5) 5
acute coronary syndrome (4) 4
c-reactive protein (4) 4
cardiovascular disease (4) 4
cardiovascular-disease (4) 4
enzyme inhibitors - pharmacology (4) 4
foam cell-formation (4) 4
group iia (4) 4
lipoprotein-associated (4) 4
lipoproteins (4) 4
phospholipases a2, secretory - metabolism (4) 4
plasma-levels (4) 4
randomized clinical-trial (4) 4
acetates - administration & dosage (3) 3
activating-factor-acetylhydrolase (3) 3
analysis (3) 3
antiinflammatory drugs (3) 3
aorta - pathology (3) 3
apolipoproteins e - deficiency (3) 3
apolipoproteins e - genetics (3) 3
atherosclerosis - enzymology (3) 3
atherosclerosis - pathology (3) 3
atherosclerotic plaque (3) 3
benzaldehydes - pharmacology (3) 3
cardiology (3) 3
cardiovascular diseases - drug therapy (3) 3
cells, cultured (3) 3
cholesterol (3) 3
clinical trials as topic (3) 3
coronary heart disease (3) 3
disease (3) 3
drug development (3) 3
drug therapy (3) 3
drugs (3) 3
e-deficient mice (3) 3
female (3) 3
group-iia (3) 3
indoles - administration & dosage (3) 3
mice, inbred c57bl (3) 3
mice, knockout (3) 3
myotoxin (3) 3
oximes - pharmacology (3) 3
phospholipase a inhibitor (3) 3
prognostic value (3) 3
risk factors (3) 3
secreted (3) 3
secretory phospholipase-a2 (3) 3
snake venom (3) 3
spla (3) 3
toxicology (3) 3
vascular inflammation (3) 3
venom (3) 3
-bromoenol lactone (2) 2
a inhibitor (2) 2
a-002 (2) 2
acid (2) 2
activation (2) 2
acute coronary syndromes (2) 2
aneurysm (2) 2
antidotes - pharmacology (2) 2
antivenom (2) 2
aorta - drug effects (2) 2
aorta - metabolism (2) 2
apoe (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Toxicon, ISSN 0041-0101, 01/2019, Volume 157, pp. 1 - 7
A need exists to develop specific and clinically useful inhibitors of toxic enzymes present in snake venoms, responsible for severe tissue damage and... 
Myotoxin | Snake venom | LY315920 | Phospholipase A | Varespladib
Journal Article
Toxicon, ISSN 0041-0101, 01/2019, Volume 157, pp. 1 - 7
A need exists to develop specific and clinically useful inhibitors of toxic enzymes present in snake venoms, responsible for severe tissue damage and... 
Snake venom | Myotoxin | Phospholipase A2 | LY315920 | Varespladib | Index Medicus
Journal Article
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, ISSN 0735-1097, 03/2014, Volume 63, Issue 9, pp. 942 - 943
Journal Article
Journal Article
EUROPEAN HEART JOURNAL, ISSN 0195-668X, 12/2012, Volume 33, Issue 23, pp. 2899 - U33
Certain members of the phospholipase A(2) superfamily of enzymes have established causal involvement in atherosclerosis, thus at least two groups of this... 
GROUP-V | GROUP-X | CARDIAC & CARDIOVASCULAR SYSTEMS | MYOCARDIAL-INFARCTION | Secretory phospholipase A | LOW-DENSITY-LIPOPROTEIN | PUBLIC-HEALTH PRACTICE | Cardiovascular disease | GROUP IIA | VASCULAR-DISEASE | Varespladib | Darapladib | FOAM CELL-FORMATION | Lipoprotein-associated phospholipase A | CARDIOVASCULAR-DISEASE | CORONARY-HEART-DISEASE
Journal Article
TOXICON, ISSN 0041-0101, 01/2019, Volume 157, pp. 1 - 7
A need exists to develop specific and clinically useful inhibitors of toxic enzymes present in snake venoms, responsible for severe tissue damage and... 
Snake venom | CROTOXIN | CRYSTAL-STRUCTURE | METALLOPROTEINASE | STABILITY | MUSCLE | MECHANISMS | BOTHROPS-ASPER VENOM | Phospholipase A | DAMAGE | Varespladib | Myotoxin | INHIBITION | PHARMACOLOGY & PHARMACY | TOXICOLOGY | LY315920 | ANTIINFLAMMATORY DRUGS
Journal Article
MOLECULAR AND CELLULAR BIOCHEMISTRY, ISSN 0300-8177, 10/2018, Volume 447, Issue 1-2, pp. 93 - 101
Secretory phospholipase A(2) (sPLA(2)) group of enzymes have been shown to hydrolyze phospholipids, among which sPLA(2) Group V (GV) and Group X (GX) exhibit... 
GROUP-V | ACTIVATION | Lipid droplet | EMERGING ROLES | GROUP-IIA | ACID | SECRETORY PHOSPHOLIPASE A | (R)-Bromoenol lactone | Varespladib | DROPLETS | CELL BIOLOGY | sPLA-GX | INHIBITION | ENZYMES | sPLA-GV | EXPRESSION | Pyrrophenone
Journal Article
by Xiao, HX and Li, HR and Zhang, DH and Li, YY and Sun, SM and Huang, CH
MOLECULES, ISSN 1420-3049, 08/2018, Volume 23, Issue 8
Snake venom is a complex cocktail of toxins which induces a series of clinical and pathophysiological manifestations in victims, including severe local tissue... 
Deinagkistrodon acutus | SKELETAL-MUSCLE | CELLS | varespladib | MYOGENESIS | BIOCHEMISTRY & MOLECULAR BIOLOGY | muscle regeneration | fibrosis | PATHOLOGY | IDENTIFICATION | CHEMISTRY, MULTIDISCIPLINARY | ASPER SNAKE-VENOM
Journal Article
Arteriosclerosis, Thrombosis, and Vascular Biology, ISSN 1079-5642, 06/2016, Volume 36, Issue 6, pp. 1090 - 1100
OBJECTIVE—Hyperlipidemia-induced endothelial cell (EC) activation is considered as an initial event responsible for monocyte recruitment in atherogenesis.... 
atherosclerosis | hyperlipidemia | endothelial cell | mitochondria | reactive oxygen species | PROGENITOR CELLS | VARESPLADIB | PHOSPHOLIPASE A INHIBITOR | CARDIOVASCULAR EVENTS | RANDOMIZED CLINICAL-TRIAL | ACUTE CORONARY SYNDROME | HEART-DISEASE | INFLAMMATION | PERIPHERAL VASCULAR DISEASE | MICE | ATHEROSCLEROTIC PLAQUE | HEMATOLOGY | Hyperlipidemias - genetics | Reactive Oxygen Species - metabolism | Apolipoproteins E - deficiency | Transcription Factor AP-1 - genetics | Atherosclerosis - genetics | Humans | Aorta - metabolism | Transcription Factor AP-1 - metabolism | Aortic Diseases - metabolism | Time Factors | Membrane Potential, Mitochondrial | Calcium Signaling | Aortic Diseases - pathology | Disease Models, Animal | Atherosclerosis - pathology | Genetic Predisposition to Disease | Lysophosphatidylcholines - pharmacology | Hyperlipidemias - metabolism | Oxidation-Reduction | Endothelial Cells - metabolism | Aorta - drug effects | Mice, Inbred C57BL | Cells, Cultured | Gene Expression Regulation | Lysophosphatidylcholines - metabolism | Gene Expression Profiling - methods | Mitochondria - metabolism | Antioxidants - pharmacology | Mitochondria - drug effects | Metabolomics - methods | Atherosclerosis - metabolism | Mice, Knockout | Aorta - pathology | Aortic Diseases - genetics | Intercellular Adhesion Molecule-1 - metabolism | Phenotype | Animals | Apolipoproteins E - genetics | Intercellular Adhesion Molecule-1 - genetics | Oxidative Stress - drug effects | Endothelial Cells - drug effects | vascular inflammation
Journal Article
Journal Article
Toxins, ISSN 2072-6651, 12/2018, Volume 10, Issue 12, p. 516
Snakebite is a global tropical disease that has long had huge implications for human health and well-being. Despite its long-standing medical importance, it... 
Cobra | Tissue damage | Antivenom | Coagulotoxicity | Venom | Snakebite | LY315920 | Coagulopathy | Varespladib | FACTOR XA | cobra | tissue damage | antivenom | FOOD SCIENCE & TECHNOLOGY | PHOSPHOLIPASE A | NIGRICOLLIS | ELAPIDAE | coagulopathy | venom | EVOLUTION | varespladib | coagulotoxicity | snakebite | SNAKE-VENOMS | TOXICOLOGY | SERPENTES
Journal Article
Journal Article
Molecular and Cellular Biochemistry, ISSN 0300-8177, 10/2018, Volume 447, Issue 1, pp. 93 - 101
Journal Article
JOURNAL OF LIPID RESEARCH, ISSN 0022-2275, 04/2009, Volume 50, Issue 4, pp. 623 - 629
Secretory phospholipase A2 (sPLA(2)) activity promotes foam cell formation, increases proinflammatory bioactive lipid levels, decreases HDL levels, increases... 
GROUP-V | CORONARY EVENTS | drugs | BIOCHEMISTRY & MOLECULAR BIOLOGY | SECRETORY PHOSPHOLIPASE A | secretory phospholipase A2 | CELL CONTENT | varespladib | ATHEROSCLEROTIC LESION FORMATION | FACTOR RECEPTOR-BETA | E-DEFICIENT MICE | lipoproteins | ANTIINFLAMMATORY DRUGS | TRANSGENIC MICE | ARTERY-DISEASE
Journal Article
Atherosclerosis, ISSN 0021-9150, 2010, Volume 212, Issue 2, pp. 357 - 366
The potential for phospholipases as targets for treating atherogenesis has become more prominent over the past year with the publication of the results of... 
Phospholipase | Secreted | Darapladib | Lipoprotein-associated | Atherosclerosis | Drug development | Varespladib
Journal Article
EUROPEAN HEART JOURNAL, ISSN 0195-668X, 04/2011, Volume 32, Issue 8, pp. 999 - 1005
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.